CLINICAL TRIALS PROFILE FOR LY3410738
✉ Email this page to a colleague
Clinical Trials for LY3410738
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04521686 ↗ | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Recruiting | Eli Lilly and Company | Phase 1 | This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 130 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma. |
| NCT04521686 ↗ | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Recruiting | Loxo Oncology, Inc. | Phase 1 | This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 130 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma. |
| NCT04603001 ↗ | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Recruiting | Eli Lilly and Company | Phase 1 | This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy |
| NCT04603001 ↗ | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Recruiting | Loxo Oncology, Inc. | Phase 1 | This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy |
| NCT05205447 ↗ | Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants | Recruiting | Loxo Oncology, Inc. | Phase 1 | The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days. |
| NCT05205447 ↗ | Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants | Recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY3410738
Condition Name
Clinical Trial Locations for LY3410738
Trials by Country
Clinical Trial Progress for LY3410738
Clinical Trial Phase
Clinical Trial Sponsors for LY3410738
Sponsor Name
